$6.47 0.0 0.0%
Last Trade - 22/02/19
| Market Cap | £n/a |
| Enterprise Value | £n/a |
| Revenue | £189.6m |
| Position in Universe | th / 6852 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 62.9 | 67.4 | 72.4 | 174.3 | 229.7 | 246.1 | +31.4% | ||||
| -99.3 | -25.7 | +8.7 | ||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | March 1, 1999 |
| Public Since | November 13, 2009 |
| No. of Shareholders: | n/a |
| No. of Employees: | 910 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 98,903,243 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 39 Shangdi Xi Road Haidian District, BEIJING, 102200, China |
| Web | http://www.sinovac.com/ |
| Phone | +86 10 56931800 |
| Contact | Helen Yang (IR Contact Officer) |
| Auditors | Marcum Bernstein & Pinchuk LLP |
As of 22/02/19, shares in Sinovac Biotech are trading at $6.47, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.
Shares in Sinovac Biotech are currently trading at $6.47 and the price has moved by -20.32% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sinovac Biotech price has moved by -47.63% over the past year.
Of the analysts with advisory recommendations for Sinovac Biotech, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Sinovac Biotech is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Sinovac Biotech is scheduled to issue upcoming financial results on the following dates:
Sinovac Biotech does not currently pay a dividend.
Sinovac Biotech does not currently pay a dividend.
Sinovac Biotech does not currently pay a dividend.
To buy shares in Sinovac Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Sinovac Biotech are currently trading at $6.47, giving the company a market capitalisation of £n/a.
Here are the trading details for Sinovac Biotech:
We were not able to load our ranking data for Sinovac Biotech
We were not able to load any forecast data for Sinovac Biotech.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinovac Biotech. Over the past six months, the relative strength of its shares against the market has been -14.63%. At the current price of $6.47, shares in Sinovac Biotech are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Sinovac Biotech.
Sinovac Biotech's management team is headed by:
Here are the top five shareholders of Sinovac Biotech based on the size of their shareholding:
